


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
DIACOMIT (stiripentol) is an anticonvulsant medication prescribed for the treatment of seizures in patients with Dravet syndrome. It is used as an adjunctive therapy alongside clobazam.
Available in both capsule and oral suspension forms, DIACOMIT is particularly important for pediatric patients aged 6 months or older, providing effective management of seizure frequency in individuals who do not respond adequately to other treatments.
Stiripentol is indicated for the treatment of seizures associated with Dravet syndrome (severe myoclonic epilepsy in infants) in patients aged 6 months and older, weighing 7 kg or more, who are taking clobazam. There is no clinical data to support the use of stiripentol as monotherapy for Dravet syndrome.
The recommended dosage of DIACOMIT is 50 mg/kg/day, administered in 2 or 3 divided doses.
